Panacea's lead program is in oncology and centers on an entirely unique and proprietary technology platform that offers substantial opportunities for the development and commercialization of an integrated set of diagnostics and therapeutics for cancer.
Panacea’s entire cancer program is based on an enzyme (protein) called HAAH or Human Aspartyl (Asparaginyl) β-Hydroxylase that plays an important role in embryonic development and growth of the fetus. After birth the HAAH gene is silenced and this protein is no longer needed. When the cells become cancerous, the HAAH enzyme is expressed again and functions to impart uncontrolled growth, movement and penetration of cancer cells into other tissues. Over-expression of HAAH is strongly associated with the progression and invasiveness of multiple cancers. This protein is prevalent on the surface of cancer cells of all types and at the edge of tumors. It is not detectable in normal cells or tissue surrounding the tumor. When this enzyme is silenced in cancer cells, the cells behave like normal cells, and if normal cells are transfected to produce this enzyme, they behave as cancer cells.
The Company has established a significant intellectual property portfolio based on the subject and several further applications currently under development.